GlassScriptPhysician profile
Stephen R Archacki
NPI 1376526053
$13,189.74
in general payments reported to CMS, 2019-2025
57 companies · $3,483 in 2025
The $3,483 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,129 · 2020: $193 · 2022: $952 · 2023: $2,719 · 2024: $3,714 · 2025: $3,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,915.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,466.82 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,182.40 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,153.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,090.05 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $948.77 | 2019-2025 | Linzess, Vraylar, Viberzi |
| Amgen INC. | $776.05 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $693.15 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $629.14 | 2019-2025 | Jardiance, Tradjenta, Ofev |
| E.R. Squibb & Sons, L.L.C. | $508.76 | 2019-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $504.57 | 2022-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $431.85 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $328.14 | 2022-2025 | |
| Astellas Pharma US INC | $299.41 | 2019-2025 | Veozah, Myrbetriq |
| Xeris Pharmaceuticals, INC. | $252.50 | 2023-2025 | Gvoke Hypopen |
| Lundbeck LLC | $251.10 | 2023-2025 | Rexulti |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Archacki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.